Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07139106 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts

StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later May 1, 2028 → Oct 1, 2028
See other at-risk trials from New York State Psychiatric Institute

Record History

  1. Start date: May 1, 2026 to Oct 1, 2026
    • Primary and study completion pushed from May 1, 2028 to Oct 1, 2028
    v4
  2. Primary and study completion dates: Sep 30, 2027 to May 1, 2028
    • Start date: Feb 1, 2026 to May 1, 2026
    v3
  3. Enrollment target: 6 to 12v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study explores how stress, suicidal thoughts, and ketamine's effects are connected in people with major depressive disorder. Stress increases the risk for suicidal thoughts, but the biological basis is unclear. Ketamine may help reduce suicidal thoughts by affecting stress-linked brain systems. This study will use smartphone tracking to monitor real-time responses to stress and positron emission tomography (PET) brain scans to study how ketamine affects brain pathways related to stress and suicidal thoughts in depressed individuals.
Trial Details
NCT Number NCT07139106
Lead Sponsor New York State Psychiatric Institute
Collaborators: American Foundation for Suicide Prevention
Conditions
(from sponsor)		 Major Depressive Disorder (MDD)
Related terms Major Depressive Disorder
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov